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ABSTRACT
Objective: Congenital heart disease (CHD) is the most frequent birth defect worldwide. The number of adult patients with CHD, now referred to
as ACHD, is increasing with improved surgical and treatment interventions. However the mechanisms whereby ACHD predisposes patients to
heart dysfunction are still unclear. ACHD is strongly associated with metabolic syndrome, but how ACHD interacts with poor modern lifestyle
choices and other comorbidities, such as hypertension, obesity, and diabetes, is mostly unknown.
Methods: We used a newly characterized mouse genetic model of ACHD to investigate the consequences and the mechanisms associated with
combined obesity and ACHD predisposition. Metformin intervention was used to further evaluate potential therapeutic amelioration of cardiac
dysfunction in this model.
Results: ACHD mice placed under metabolic stress (high fat diet) displayed decreased left ventricular ejection fraction. Comprehensive
physiological, biochemical, and molecular analysis showed that ACHD hearts exhibited early changes in energy metabolism with increased
glucose dependence as main cardiac energy source. These changes preceded cardiac dysfunction mediated by exposure to high fat diet and were
associated with increased disease severity. Restoration of metabolic balance by metformin administration prevented the development of heart
dysfunction in ACHD predisposed mice.
Conclusions: This study reveals that early metabolic impairment reinforces heart dysfunction in ACHD predisposed individuals and diet or
pharmacological interventions can be used to modulate heart function and attenuate heart failure. Our study suggests that interactions between
genetic and metabolic disturbances ultimately lead to the clinical presentation of heart failure in patients with ACHD. Early manipulation of energy
metabolism may be an important avenue for intervention in ACHD patients to prevent or delay onset of heart failure and secondary comorbidities.
These interactions raise the prospect for a translational reassessment of ACHD presentation in the clinic.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Successful corrective interventions for CHD malformations have led to
improved patient survival into adulthood, causing a staggering 60%
increase in patients presenting with adult congenital heart disease
(ACHD) [1,2]. Consequently, the number of ACHD genetically predis-
posed individuals is on the rise, affecting approximately 2.4 million
patients in the US alone [2]. Although early corrective interventions for
CHD are successful, CHD patients have a higher risk of developing
progressive cardiac dysfunction during adulthood. Among the ACHD
population the prevalence of comorbidities such as renal, pulmonary,
hepatic, and vascular dysfunctions, as well as psychiatric diagnosis are
elevated. These major health risks drastically increase the morbidity
and mortality of ACHD patients [3]. The high prevalence of associated
metabolic disorders in ACHC also merits further investigation, given the
multiple prophylactic options currently available in the clinic.
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The continuous decline in physical activity and increased caloric intake
has resulted in an obesity epidemic in developed countries that is the
major health risk of the 21st century. It is estimated that approximately
63.3% of the American population is currently overweight or obese [4].
ACHD intrinsic congenital heart dysfunction is exacerbated by external
environmental factors, including obesity, diabetes, and/or high blood
pressure, all of which can trigger heart failure [5e7]. Therefore, it is
imperative to understand why today’s lifestyle set ACHD patients at an
even higher, life-threatening risk than the general population. Despite
the existence of large epidemiological datasets, not much is currently
known about how ACHD predisposes patients to heart failure upon
metabolic stress. The present study focuses on how obesity affects
cardiac function in our recently characterized ACHD model [8,9]. Using
genetically predisposed mice [9] and diet as a cardiac stressor, we
describe a preexistent imbalance in the metabolic state of ACHD
hearts. Development of obesity increases the severity of heart
dysfunction. This interaction between genetic and metabolic factors
ultimately leads to the clinical presentation of heart failure in ACHD.
Modulation of energy utilization by Metformin, a drug widely used to
treat type 2-diabetes, prevents cardiac dysfunction in ACHD/obesity
model and could therefore be considered a preventive intervention for
heart failure in ACHD. Our observations also suggest that ACHD is a
complex, multifactorial disease that can be modulated by changes in
global metabolism. Patients at risk for ACHD show intrinsic metabolic
dysfunction that is aggravated by exposure to a modern lifestyle
environment leading to cardiac dysfunction, and therefore should be
differentially monitored.
2. METHODS
2.1. Mouse lines
Nkx2-5C/þ and Nkx2-5183P/þ (ACHD) heterozygous mice have been
previously characterized [9]. All mice were maintained on a C57BL/6J
background, housed at Monash Animal Services, Australia, or at The
Jackson Laboratory, USA. This investigation conforms with the Guide
for the Care and Use of Laboratory Animals published by the US Na-
tional Institutes of Health (NIH Publication No. 85e23, revised 1996)
and requirements under the ethics application MARP-2011-175
(Monash University) and ACUC 16011 (The Jackson Laboratory).
Control mice used were either Nkx2-5C/þ (homologous recombination
replacing the I residue with itself; i.e. control¼ C) or wild-type (WT). No
significant molecular or physiological differences were observed be-
tween these two control groups [9]. Whenever possible, control lit-
termates were used for the experiments. All experiments were
performed on adult males.
2.2. Feeding regimen
Six-week-old male mice were subdivided into four experimental
groups according to genotype and feeding regimen (control Low
Fat (LF), control High Fat (HF); ACHD LF and ACHD HF). Throughout
the study, two time-point cohorts were used: short (weeks 6e15)
and long (weeks 6e30) feeding regimens. All mice were single
housed under normal environmental conditions (21.5  1 C with
a lightedark cycle of 12 h:12 h). For metformin studies, four
siblings male mice were housed together during treatment. Food
and water were accessible ad libitum. Low Fat diet (SF13-081/
D12451; total calculated digestible energy from lipids: 12.0%, total
calculated digestible energy from protein: 25.8%) and High Fat diet
(SF04-001; total calculated digestible energy from lipids: 43.0%,
total calculated digestible energy from protein: 21.0%) were pur-
chased from Specialty Feeds, Pty Ltd. (Australia) and Research
Diets Inc. (USA). Metformin at the concentration of 5 mg/mL was
added to the water from 8 weeks of age until the end of the
protocol at libitum. Weight and food consumption were recorded
weekly at 10 a.m  2 h from the age of 6 weeks until week 15
for short feeding regimen groups and further calculated at week
30 for long feeding regimen groups.
2.3. Histology
Mice were euthanized via CO2 asphyxiation, perfused with HBSS
(Thermo), followed by heart dissection. Hearts were further incubated
for 5 min in 60 mM KCl for synchronization of heart cycle before fix-
ation. Tissues were fixed in 4% PFA at 4 C overnight and further
processed for paraffin sectioning following standard dehydration and
embedding protocols. Adult thyroids were sectioned at 14 mm thick-
ness, adult hearts at 10 mm thickness. Masson’s Trichrome staining
was performed by the Monash Histology Facility. For myocyte area
measurements, transverse sections were stained with Wheat Germ
Agglutinin Alexafluor 488 conjugate (WGA, Thermo). All images were
obtained using Olympus DotSlide (Japan). Mitochondrial density was
analyzed by immunofluorescence on 20 mm heart cryosections using
TOMM20 rabbit polyclonal antibody (Abcam) raised against the
Translocase of Outer Protein Membrane 20 gene (Tomm20). Confocal
Z-stack images were performed using Leica SP8. Myocyte area and
fluorescent intensity were measured using FIJI software with three
replicates for each genotype. For TEM, 50 mg of cardiac tissue was
processed by the JAX histology core, and sections were evaluated
using JM-1230 microscope (JEOL) coupled to AMT 2K camera
(Advanced Microscopy Techniques). Statistical significance of data
was determined by ANOVA or Student’s t-test.
2.4. Magnetic Resonance Imaging (MRI), Echocardiography and
ECG analysis of cardiac function
15- and 30-week old adult mice were anesthetized with 2%  0.2%
isoflurane for non-invasive imaging in a prone position. For MRI, im-
aging was performed in spontaneously breathing mice in a 9.4 T MRI
scanner (Agilent, USA) to assess left ventricular and right ventricular
chamber dimensions in systole and diastole using T1 and T2-weighted
anatomical sequences. Breathing was also monitored to avoid mea-
surement distortions during the breathing cycle. Measurements of
cardiac function were performed using Segment software [10]
analyzed blinded to genotype by two independent researchers.
Echocardiogram analysis was performed using Vevo 2100 (FUJIFILMS
Visualsonics). ECG was recorded in anesthetized mice using Powerlab
data acquisitions system (ADInstruments, USA) and analyzed using
LabChart8 software (ADInstruments, USA).
2.5. Metabolic measurements
For accurate measurement of weight and body fat composition, we
performed dual-energy X-ray absorptiometry (DeXa) using Lunar PIX-
Imus Densitometer (GE Medical Systems, USA) or Echo MRI (USA).
For DeXa analysis, mice were anesthetized with 1.7%  0.2% iso-
flurane. Whole-body metabolic changes in activity and energy
expenditure were assessed using individually housed animals in the
comprehensive cage monitoring system Promethion (Sable Systems
International, USA). Mice were maintained on a 12 h light:dark cycle
with access to food and water ad libitum in cages undisturbed for
120 h to collect CO2 production, O2 consumption, locomotor activity,
body mass, and food and water intake. Voluntary exercise capacity in
running wheels (Med Associates Inc, USA) was measured by recording
running distance and circadian activity for 5 continuous days.
Metabolite levels of cholesterol, triglycerides, glucose and NEFA were
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quantified from mouse sera using the Clinical Assessment Services,
The Jackson Laboratory.
2.6. Adult cellular respiration analysis
Mitochondrial function in mechanically permeabilized fibers from the
left ventricular free wall was evaluated using the Oxygraph-2k
Respirometer (Oroboros Instruments, AT). Fibers were added to the
oxymetry chamber containing MiR06 media (EGTA 0.5 mM, MgCl2
6H2O 3 mM, Lactobionic acid 60 mM, Taurine 20 mM, KH2PO4 10 mM,
HEPES 20 mM, D-Sucrose 110 mM, BSA 1 g/l, Catalase 280 U/ml, pH
7.1, at 30 C) with 25 mM Blebbistatin [11]. Fatty acid oxidation and
Complex I protocols were adapted from a previously published protocol
[12] and depicted in Figure 4E.
2.7. Metabolomics and western blot analysis
Unbiased discovery metabolite platform was performed at the West
Coast Metabolomics Center (UC Davis, USA). Biventricular apex frag-
ments were snap frozen in N2 and shipped to the Center in dry ice. The
metabolomics platform used consisted of four different combinations
of liquid chromatography (LC) and mass spectrometry ionization using
Agilent 6890 GC (Agilent Technologies, USA) followed by Pegasus III
TOF MS (LECO corporation, USA). Relative abundance of 273 unique
metabolic features (109 metabolites of known structures and 164
unique features of unknown structure), normalized to internal stan-
dards were measured at each time point. Metaboanalyst 3.0 software
[13] was used for bioinformatics analysis. Interquartile range based
filtering was used to remove features unlikely to be used for modeling
purposes [14]. The data were log transformed and autoscaled [15].
Fold Change (FC) analysis (before column normalization), t-tests, and
volcano plots were generated comparing the mutant samples with the
control samples at each time point. Protein changes were analyzed by
western blot using proteins extracted from biventricular fragments as
previously described [9]. Antibodies used are described in
Supplementary Table 4.
2.8. Functional annotation enrichment analysis of Nkx2-5 ChIP
peak regions
Publicly available chromatin immunoprecipitation followed by deep-
sequencing (ChIP-seq) data (GSE35151) [16] was re-analyzed by our
group. Unsupervised enrichment analysis of genome-wide occupancy
profile of Nkx2-5 in adult mouse whole heart was performed using
Genomic Regions Enrichment of Annotations Tool [17]. We performed
gene ontology (GO) analysis using GREAT default setting (5 kb
proximal þ 1 kb basal, up to 1 Mb distal, mm9 reference genome)
calculating statistical enrichments by associating genomic regions with
nearby genes and applying the gene annotations to the regions.
2.9. RNAseq, bioinformatics and validation
Ventricular heart samples from 15-week old adult males of each ge-
notype (Nkx2-5183C/þ, WT, and Nkx2-5183P/þ mice) on a high fat diet
were used as biological replicates for RNA sequencing. Total RNA
extraction was performed using the mirVana kit (Thermo, USA) and
cleared of genomic DNA contamination using in column DNAse
treatment (Qiagen, Germany). Samples were further processed by the
Medical Genomics Facility at Monash University. RNA-seq data (paired-
end reads of 100 nt) were trimmed for quality and adapter contami-
nation using Cutadapt [18] as implemented in Trim Galore (Phred
quality threshold of 28, minimum adapter overlap 3 nt, adaptor
sequence AGATCGGAAGAGC). It was then mapped to the mouse
genome (mm10) using STARv2.4.0 [19], and reads were tallied within
gene features using HTSeq [20]. From the resulting read-count matrix,
genes with more than 10 reads in any sample were kept and differ-
entially expressed genes were called using limma.voom [21]. Targets
with a FDR cut-off of 0.1 were further selected for validation using
qPCR. cDNA synthesis was performed in the same samples using
Superscript VILO (Thermo) followed by SYBR green reactions (Roche,
USA) and analyzed using the LightCycler480 (Roche, USA). Relative
quantification was obtained using Hprt as a normalizer. Primers used
are described in Supplementary Table 4. Ingenuity Pathway Analysis
(IPA) software (Qiagen Bioinformatics, Germany) was used to analyze
differentially regulated pathways and functions in datasets.
2.10. Statistics
Data as presented as a mean  SEM. Statistical significance of data
was determined by ANOVA and Student’s t-test. P values < 0.05 were
considered significant.
3. RESULTS
3.1. ACHD mice show increased susceptibility to weight gain and
development of obesity
In a previous study, we described a point mutation in the NKX2-5 gene
found in a familial ACHD cohort. We engineered the same human
mutation in mice and showed that our model reproduced all clinical
features of the disease [9]. To explore the interplay between ACHD,
metabolism, and heart function, we subjected ACHD mice to control
conditions under low fat (LF) and high fat (HF) diet as a metabolic
stressor (Figure 1A). At the onset of the feeding regimen (6 weeks of
age), ACHD mice had significantly lower weight when compared to
control mice (Supplementary Figure 1). Surprisingly, after 9 weeks of
diet, ACHD mice showed a significantly higher weight gain when
compared to control mice on HF diet. The increased weight gain was
attributed to higher body fat, as lean body weight did not differ be-
tween groups (Figure 1B). No difference in weight was observed be-
tween experimental groups subjected to LF diet. In summary, ACHD
mice showed comparatively higher fat accumulation and weight gain
when subjected to higher caloric intake, indicating that ACHD and diet
have combined additive effects on weight gain and therefore ACHD
mice are more predisposed to develop obesity.
3.2. Obesity triggers cardiac dysfunction in ACHD
We have previously shown that most disease features developed in the
ACHD model are functionally compensated in homeostasis in early
adulthood [9], except for RV dysfunction, defined by a significant
decrease of right ventricular ejection fraction (EF) (Figure 1C,D). Short-
term 9-week HF feeding regimen (15 weeks of age) did not significantly
affect cardiac function (Figure 1D, Supplementary Figure 2A). However,
the long-term 24-week regimen (30 weeks of age) caused a significant
decrease in EF for both right (RV) and left (LV) ventricles, as well as
enhanced RV and right atrial (RA) dilation in ACHD mice (Figure 1C,D;
Supplementary Figure 2B). Once subjected to HF diet, murine ACHD
hearts showed increased wall thickness, eccentric ventricular hyper-
trophy with dilation, and an increase in transverse myocyte area
(Figure 1E,F). Hypertrophy was also evident in ACHD mice subjected to
LF diet but was enhanced on HF diet. No hypertrophy was seen in
control mice independent of the diet of choice, demonstrating the
importance of genetic predisposition for the hypertrophic response. In
summary, ACHD mice showed several morphological abnormalities and
cardiac dysfunction prior to the development of Heart Failure with
Preserved Ejection Fraction (HFpEF) [22] when subjected to metabolic
stress (HF diet), suggesting that challenging a weakened ACHD heart
with metabolic stress accelerates progression to heart failure.
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3.3. Obesity triggers global metabolic energy dysfunction in ACHD
mice
When provided with voluntary running exercise, ACHD mice on HF diet
at 30 weeks displayed significantly reduced physical performance, as
measured by decreased running distance (dark cycle; Figure 1G). No
significant changes were detected in time spent on the wheel, food
intake and activity, indicating that ACHD mice were active but not
running at the same speed as control mice (Supplementary
Figure 3A,B). Overall energy expenditure of mice on HF diet was
also significantly reduced in ACHD mice (Figure 1H), with decreased
levels of O2 consumption (volume O2  VO2) and CO2 production
(volume CO2  VCO2) rates, while still maintaining normal respiratory
Figure 1: Effect of high fat diet on ACHD hearts and body metabolism. (A) Experimental design, treatment groups, and analyses end-points. (B) Lean and fat mass
measurements of body weight for control and ACHD mice under low (LF) and high (HF) diet at the 30-week time-point. (C) Whole-mount view and trichrome stained histological
sections of control and ACHD hearts at 30 weeks. (D) Left-ventricular (LV) ejection fraction (EF) measurements of cardiac function of control and ACHD animals under LF and HF
diets at the early (15-week) and late (30-week) time-points. (EeF) Transverse hematoxylin and eosin stained sections (E) and quantification of myocyte cross-sectional area of WGA
and DAPI stained sections (F) of control and ACHD animals under LF and HF diets at the 30-week time-point. (GeH) Running capacity and energy expenditure of ACHD and control
mice under LF and HF at 30 weeks, showing distance traveled (G) and energy expenditure (H) during dark (active) and light (resting) light cycles. N ¼ 6 per experimental group;
Mean  SEM, Student’s t-test; *p < 0.05; **p < 0.01; ****p < 0.0001.
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exchange ratio (RER). These changes were not observed when ACHD
mice were subjected to a Western diet formulation (manuscript under
preparation), which contains high sugar [23], indicating that cardiac
dysfunction was likely mediated by increased availability of fatty acids
in the HF diet. Together, these data confirm that nutritional imbalance
exacerbates heart dysfunction in ACHD mice.
To determine how global metabolism was affected, we monitored
serum levels of glucose and lipids of ACHD mice on HF diet. While no
significant changes were seen at 6 weeks, higher plasma levels of
triglycerides and a tendency towards increased cholesterol and free
fatty acids (NEFA) at 30 weeks was observed (Figure 2A). Glucose
handling was also affected in ACHD mice on HF diet, with an improved
response when compared to control mice (Figure 2B, Supplementary
Figure 4).
3.4. Primary heart metabolic dysfunction in ACHD mice is driven by
changes in energetic substrates
NKX2-5 is a transcription factor essential for heart formation during
embryonic development, although the molecular consequences of its
dysfunction in adult hearts are still largely unknown. Analysis of
chromatin immunoprecipitation followed by deep-sequencing (ChIP-
seq) of adult hearts using gene ontology (GO) and molecular signature
database (MSigDB) revealed that the human NKX2-5 protein binds the
promoter regions of essential genes associated with cellular meta-
bolism and energy production (Figure 3A, Supplementary Table 1), a
previously unrecognized phenomenon. To further explore the molec-
ular mechanisms underlying the primary metabolic alterations in ACHD
hearts, we performed transcriptome analysis (RNAseq) on short-term
HF-fed mice, before cardiac dysfunction was established. This anal-
ysis focused on investigation of genes that were differentially
expressed between obese control and ACHD mice, to expose molecular
differences of the metabolic stress model (ACHD þ obesity). Relative
quantification showed 1264 genes differentially expressed between
control and ACHD obese hearts. Ingenuity Pathway Analysis (Qiagen)
revealed 41 predicted upstream regulators of affected genes
(Figure 3B), including cardiac transcription factors known to partner
with NKX2-5, four of which are involved in cardiogenesis and cardiac
function. The canonical pathway of cardiac hypertrophy was signifi-
cantly changed in ACHD (z-score ¼ 1.347; p-value ¼ 0.00011),
confirming our finding of eccentric hypertrophy (Figure 1E,F).
Among genes involved in the hypertrophic response, Rock and Mlc
complexes and a large subset of other effector genes such as Gata4,
Figure 2: Metabolic disturbances in ACHD hearts under high fat diet. (A) Serum glucose, lipid analyses, and (B) glucose tolerance test (GTT) in ACHD and control mice at 6
weeks (before start of diet) 30 weeks (long-term diet end-point). N  6, Mean  SEM, Student’s t-test, *p < 0.05, **p < 0.01. GLU e glucose; CHOL e cholesterol; TAG e
triglycerides; NEFA e non-esterified free fatty acid.
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Hand2, Mef2, and p300 were up regulated in ACHD mutants
(Supplementary Figure 5). These genes trigger an increase in
contractility, leading to long-term cardiac hypertrophy [24e28].
Furthermore, eIF4E (mRNA cap-binding protein) and Mlnk1 (eIF4E
kinase), known essential regulators of cell size control and global
protein synthesis, were also affected in ACHD hearts. Interestingly,
37% of upstream regulators were associated with metabolic pathways
and lipid processing, including Srebf1, Nr1h2-3, Insr, and ApoE,
among others. This analysis corroborates the global whole-body
metabolic data, indicating that disturbances in heart metabolism
precede progression to heart dysfunction in ACHD.
Another affected pathway was PPAR signaling, where Ppara, Prkaa1,
and Prkaa2 were highlighted as potential regulators in ACHD mice.
These proteins are key components in fatty acid metabolism and are
normally activated to compensate for energy deprivation, which is a
common feature of heart failure [29,30] (Figure 3B). Transcriptional
Figure 3: NKX2-5 regulates energy handling in adult hearts. (A) Bioinformatics analyses of ChIP-seq against NKX2-5 in adult hearts (GEO GSE5151). Genes involved in
metabolism are highlighted in red in both Go Biological Process and Molecular Signature Database (MSigDB) resources. (B). Ingenuity Pathway Analysis (IPA) of genes differentially
regulated in obese ACHD heart RNAseq data reveals various upstream regulators for metabolism (red) and heart development (blue) processes. (C) qPCR validation of RNAseq data,
showing differential expression of genes associated with energy flexibility in ACHD mice under LF or HF diet at 15 weeks. Transcripts involved in fatty acid oxidation (Fasn, Acaca,
Acam5, CD36, Fabp3), glucose handling (Pde3a), ketone metabolism (Bdh1, Hmgc2), NAD production (Parp3, Me1, Idh1) and mitochondrial uncoupling (Ucp3) were tested. Data
presented as fold expression compared to control samples normalized by Hprt levels. N ¼ 3; Mean  SEM, Student’s t-test, *p < 0.05, **p < 0.01; ***p < 0.001, ****p < 0.0001.
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changes directly linked to metabolism were further confirmed by qPCR
(Figure 3C). In particular, decreased levels of Fasn and Acaca and
increased levels of Acsm5 indicated marked reduction of fatty acid
synthesis and increased fatty acid oxidation, presumably via loss of
inhibition of CPT1 [31], whereas Fabp3 and CD36 fatty acid receptor
transcripts were not changed, suggesting no alteration in fatty acid
uptake. In agreement with these observations, increased levels of
Pde3b suggested enhanced glucose metabolism, although no signifi-
cant changes were seen in Insr expression. Ketone body metabolism
gene Bdh1 showed decreased levels, while Hmgcs2 was increased
[32].
Genes associated with mitochondrial uncoupling/protection (Ucp3) and
NADþ metabolism (Me1, Idh1, and Parp3) were also affected. Most of
these genes are normally activated in heart failure [30]. These changes
in gene expression are likely associated with the shift in energy
signature [33,34], indicating that ACHD mice show imbalanced energy
utilization, and confirm that metabolic changes in ACHD mice are
enhanced by HF diet and precede heart failure.
3.5. Imbalanced cardiomyocyte energy handling capacity precedes
heart dysfunction in ACHD
To further characterize molecular mechanisms associated with onset
of ACHD progression to heart failure, we performed comprehensive
metabolic and physiological analysis in early adulthood, before ACHD
mice develop cardiac dysfunction. This allowed us to filter out changes
that are not directly caused by cardiac dysfunction. At 8 weeks of age,
ACHD mice showed a small but significant decrease in body weight
compared to control wild-type mice, associated with decreased lean
mass (Supplementary Figure 1), although no changes were observed
in energy expenditure, VCO2/VO2 consumption or voluntary exercise
capacity (Supplementary Figure 6AeC). No significant changes were
observed in cardiac electrical activity (Supplementary Figure 7), other
than increased spread of the QRS interval, consistent with the well-
established role for NKX2-5 in the maintenance of the conduction
system in mouse models and patients [35e38]. Echocardiographic
(Echo) analysis of heart function showed small changes in left ven-
tricular function but normal ejection fraction, indicating that imbalance
of NKX2-5 protein activity can be compensated for to ensure adequate
heart function in early adulthood (Supplementary Table 2).
We have previously observed decreased mitochondrial respiratory
capacity in neonatal ACHD cardiomyocytes [9]. Therefore, we inves-
tigated cellular respiration and energy handling in young ACHD hearts
at 8e10 weeks of age. Mitochondrial morphology was not changed in
ACHD cardiomyocytes compared with controls (Figure 4A), but a sig-
nificant decrease in mitochondrial density was observed (Figure 4Be
D). In agreement with the data obtained in neonatal cardiomyocytes
[9], mitochondrial function in left ventricular free wall fibers of the
young adult heart revealed tendency to reduced oxygen flux and fatty
acid oxidative capacity in ACHD hearts (Figure 4E). Unbiased global
metabolomics (untargeted GCMS analysis) showed a significant
Figure 4: Mitochondrial function and energy handling in ACHD hearts. (A) Transmission electron micrograph of control and ACHD muscle fibers showing size and shape of
mitochondria. (B) Confocal imaging of transverse myocardial sections of control and ACHD hearts showing mitochondrial density (green signal e TOMM20) over nuclear staining
(DAPI) and cardiomyocyte area staining (red e WGA). (C) Quantification of TOMM20 immunofluorescence or (D) protein expression ACHD and control hearts at 10 weeks (N ¼ 3).
(E) OROBOROS O2k Respirometer oxygen flux analysis of ACHD and control hearts. CI ¼ complex I; CII ¼ complex II; FAO ¼ fatty acid oxidation; M ¼ malate, G ¼ glutamate;
P ¼ pyruvate; ROX ¼ residual oxygen flux; (N ¼ 6/group). (F) Metabolomics analysis demonstrating enrichment for glycolysis (red dots), ketone (green dot), glycogen (maroon dot),
TCA cycle (orang dot) and AMP (black dot) metabolites in ACHD hearts at 8 weeks (N ¼ 6). (G) Up-regulated metabolites and processes shown in F highlighted in green. (H) Western
blot and quantification of enzymes associated with glucose (PDH), FOA (CPT-1), ketone (BDH1) and energy sensing (AMPK/phospho-AMPK) (N ¼ 3). Results shown as
Mean  SEM, Student’s t-test, *p < 0.05, ****p < 0.0001.
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increase in glycolysis and a small decrease in ketone and fatty acid
oxidation (FAO) metabolites in ACHD hearts (Figure 4F,G and
Supplementary Table 3), in particular glucose-1P, glucose 6-P, fruc-
tose 6-P for glycolysis and 3-hydroxybutyric acid for ketone meta-
bolism. Furthermore, AMP levels were increased in ACHD hearts but
this alteration did not trigger differential AMPK activation (Figure 4G,H),
suggestive of failure to respond to energetic imbalance in mutant
hearts. Metabolomic changes were further confirmed by western blot
of heart samples, which revealed a significant increase in PDH
(Glucose metabolism), small decrease in CPT1 (Fatty Acid metabolism)
and BDH (Ketone metabolism) (Figure 4H). These data suggest a shift
from FAO towards increased glycolysis in ACHD myocytes, reminiscent
of the fetal energetic program. Increased glucose dependency is an
adaptive response to maintain heart function under stress conditions
[32,39,40]. The observed changes in cardiomyocyte energetic path-
ways indicate that disturbances in metabolic state precede heart
dysfunction in ACHD and therefore represent valuable parameters to
measure predisposition to heart failure.
3.6. Intervention on energy metabolism by metformin prevents
cardiac dysfunction in ACHD
Given the newly identified role for Nkx2-5 in regulating metabolism in
ACHD hearts, we tested if early pharmacological intervention on global
metabolism could prevent heart disease progression in ACHD mice.
Young mice under HF diet were treated with metformin, a widely used
FDA-approved drug used to treat type 2 diabetes (Figure 5A). Met-
formin acts by improving metabolism and increasing glucose sensi-
tivity, FAO utilization, and mitochondrial function [41], all processes
Figure 5: Heart function and body metabolism in metformin treated animals under HF diet. (A) Experimental design and HF diet/metformin treatment groups. (B) Glucose
handling in ACHD and control mice under metformin treatment at 30 weeks. (C) Body weight measurements of control and ACHD mice under metformin treatment at the early (15-
week) and long (30-week) treatment regimens. (D) Cardiac function in control and ACHD mice treated with metformin at 15 and 30 weeks under HF diet (N ¼ 6). (E) Quantification
of mitochondrial density using immunofluorescence for TOMM20 (N ¼ 2) in control and ACHD animals under metformin treatment (N ¼ 2). (F) Trichrome staining of transverse
heart sections. Data shown as Mean  SEM, Student’s t-test, *p < 0.05, **p < 0.01; ***p < 0.001. HFD e high fat diet; Met e metformin; BW e body weight; EF e left
ventricular ejection fraction; Vol;d e left ventricular end diastolic volume; Vol;s e left ventricular end systolic volume.
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found dysregulated in ACHD hearts. Both control and ACHD mice
treated with metformin showed significant decrease in basal levels of
glucose during fasting and improvement in glucose handling
(Figure 5B). Normalization of glucose tolerance curves by basal
glucose levels showed that ACHD mice initially display better glucose
handling when compared to control mice, but metformin treatment had
no effect on ACHD mice (Supplementary Figure 8). During metformin
treatment, an early effect in fat mass gain (not shown) was seen in
control mice only (15 weeks of age; 9 weeks of treatment), while both
control and ACHD mice showed reduced body weight with longer
treatment (30 weeks of age; 22 weeks of treatment) (Figure 5C). Early
differences in weight loss between control and ACHD animals might
reflect differential glucose metabolism (Figure 2B). As detected earlier,
ACHD mice at 15 weeks had a small decrease in EF when compared to
control. Short metformin treatment led to increased diastolic and
systolic volumes that were independent of genotype (Figure 5D, upper
panel). At 30 weeks of age (22 weeks of treatment) metformin
treatment reverted heart dysfunction on ACHD mice, normalizing EF to
control levels by changes in both diastolic and systolic functions when
compared to no-metformin ACHD mice (Figure 5D, lower panel). ACHD
hearts maintained structural (hypertrophy, Figure 5E) and metabolic
(mitochondrial content, Figure 5F) abnormalities upon long-term
metformin treatment. Serum analysis of lipids showed that metfor-
min treated mice displayed decrease in circulating cholesterol (CHOL)
and free fatty acids (NEFA), while no significant changes were seen in
triglycerides (Figure 6A, upper panel). Again, no significant differences
were seen between control and ACHD mice. As previously seen, ACHD
mice display lower glucose basal levels when compared to control.
Under metformin treatment, a significant decrease in glucose was
seen in controls, while decreases in ACHD mice did not reached sig-
nificance (Figure 6A, lower left panel). It is important to note that not all
animals reacted to metformin treatment; 2/6 in control; 1/4 in ACHD
were outliers and still showed high levels of circulating glucose.
Chronic exposure to high fat diet has been associated with increased
lipid liver deposition, leading to non-alcoholic fatty liver disease
(NAFLD) that can progress to hepatic steatosis. Chronic treatment with
metformin was able to revert fat deposition in both control and ACHD
mice, leading to decreased LDH and SDH serum levels (Figure 6A, left
panels), decreased steatosis (Figure 6B) and increased glycogen
accumulation in the liver (Figure 6C). These data demonstrate that
modulation of energy metabolism by metformin, acting both at the liver
and heart, can be safely used for treatment of cardiac dysfunction
mediated by obesity in ACHD.
4. DISCUSSION
Using murine modeling, we demonstrate that changes in energy
flexibility is a hallmark of ACHD hearts at early adulthood, and that
Figure 6: Liver damage in metformin treated animals under HF diet. (A) Serum analysis of 30 week high fat-diet control and ACHD mice showing levels of circulating lipids,
i.e. cholesterol (CHOL), non-esterified fatty acids (NEFA) and triglycerides (TRIG), as well as measurements of liver function glucose, lactate dehydrogenase (LDH) and sorbitol
dehydrogenase (SHD). (B) Histological liver sections showing pathology of control and ACHD animals under HF diet with or without metformin treatment. Pale areas denote macro
and micro lipid vesicles. (C) Periodic Acid Schiff (PAS) staining of control and ACHD liver sections shows staining for glycogen (dark purple). Data shown as Mean  SEM, Student’s
t-test, *p < 0.05, **p < 0.01; ***p < 0.001, ****p < 0.0001. Met e metformin.
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metabolic imbalance is strongly associated with the progression to
heart ACHD heart dysfunction in obesity. Our data show a series of
alterations in metabolic substrates that precede cardiac dysfunction in
ACHD mice and that pharmacological intervention with metformin can
be used to prevent pathological metabolic changes and consequently
retain normal heart function. By demonstrating that Nkx2-5 mutations,
known to cause congenital cardiac malformations, are responsible for
primary defects in the metabolic capacity of the heart, this study
highlights how CHD genes can directly impact cardiac energy utiliza-
tion. The heart is very sensitive to metabolic imbalance; given the low
oxygen and high glucose availability provided by the mother, embry-
onic and early neonatal hearts display a high dependence on glycol-
ysis. After birth, cardiac metabolism is shifted to fatty acid, which is a
more efficient source of energy to sustain the increased mechanical
demand of the adult heart [42]. Although>95% of the ATP produced in
the adult heart derives from oxidative phosphorylation, energetic
flexibility is essential for adaptation of heart function to physiological
changes. Decreased flexibility is also associated with pathological
states [39,42], as energy products such as ATP, acetyl-CoA and
diacylglycerides directly impact on heart contractility and act as second
messengers controlling heart function [39].
Given the high energetic demand of the heart and the mitochondrial
role in controlling energy consumption, generation of reactive oxygen
species and apoptosis, mitochondrial defects are strongly associated
with cardiac dysfunction [43]. The decreased mitochondrial density in
ACHD hearts suggests a primary defect in mitochondrial biogenesis, in
which further investigation is merited. Mitochondrial dysfunction is also
supported by the observed decrease in cellular respiration and
impaired energetics in ACHD hearts, where early changes in cardiac
metabolism lead to increased dependency on glycolysis and decreased
metabolic flexibility. Altered glucose metabolism is one of the drivers of
the hypertrophic response and an early marker of heart disease pro-
gression [44], which could be adaptive under a homeostatic condition,
but triggers heart dysfunction once a second metabolic stress (such as
obesity) is imposed.
Despite the extensive energetic abnormalities in ACHD hearts, no
evidence of lipotoxicity was found in histological analyses of heart
sections (not shown), although important changes in lipid distribution
were detected in the metabolomic analyses. Given the decreased
energetic flexibility and fatty acid oxidation coupled with increased fatty
acid availability in ACHD/obesity, it is possible that lipotoxicity may play
a role in the later stages of disease progression.
In addition to intrinsic cardiac structural and metabolic changes, there
is a strong possibility that other extrinsic changes to the heart may
contribute to the cardiac dysfunction in our ACHD/obesity model. The
full knockin approach used in this work mimics the pathology of the
mutation in the heart but also affects other sites where Nkx2-5 is
expressed, including the tongue, thyroid, central nervous system,
thymus liver, spleen and gut, among others, when enzymatic tech-
niques are used for amplification of signal detection, such as in situ
hybridization and transgenic beta-galactosidase while in adults cardiac
expression is highly predominant [45e47]. Such sites are normally
neglected when cardiovascular analyses are performed. In the thyroid,
Nkx2-5 is transiently expressed during early development and has
shown to control thyroid gene expression [48,49]. Nkx2-5 mutations
outside of the homeodomain have been linked to thyroid dysmor-
phogenesis in patients [49]. We are currently investigating the role of
Nkx2-5 in thyroid development and heart function using conditional
deletion approaches. Preliminary analysis of hematocrit in ACHD adult
mice has shown no significant differences in blood cell composition
(data not shown). It is also possible de novo expression of Nkx2-5 in
disease states modifies the cardiovascular phenotype, as seen in
atherosclerotic plaques in ApoEedeficient mice and patients with
pulmonary hypertension [50,51]. However, mice do not normally
develop atherosclerosis. Despite these caveats, our work strongly
supports a direct action of Nkx2-5 as a controller of heart metabolism.
Metformin has known cardioprotective effects and limits cardiovas-
cular events in patients [52,53], regulating global and tissue meta-
bolism via complex mechanisms that are not completely understood.
Metformin also acts by reducing hepatic glucose production by the gut
and by increasing glucose organ sensitivity [54], and has been pre-
viously shown to protect against cancer in NAFLD models [55e57].
Despite our best efforts, we have not detected any global metabolic or
structural cardiac changes associated with the improved ACHD heart
function upon metformin treatment in our model. Furthermore, the
known action of metformin in the liver, also detected in this study,
might contribute to the cardioprotective action on the treatment. Other
possible mechanisms of action are currently under investigation in our
group. At the cellular level, metformin likely acts via AMPK-dependent
and -independent mechanisms to modulate mitochondrial and lyso-
some function [41]. Interestingly, despite the early detection of high
levels of ATP in ACHD hearts at 8 weeks, no changes in AMPK were
detected, suggesting a possible impairment of the AMPK signaling
pathway, or an AMPK-independent mechanism of action (Figure 4G,H).
Recent studies have shown that chronic exposure to metformin in-
creases lifespan in mice [58,59] and has beneficial effects in cancer
treatments [60] and cardiovascular dysfunction [52,61e64], albeit
some divergence between preclinical and clinical trials for metformin
in humans have been described as seen for non-diabetic STEMI pa-
tients [53]. Cellular uptake of metformin is controlled by organic cation
transporters (OCT) belonging to the Slc22a gene family. Expression of
OCT1 and OCT3 have been described in the heart [65]. Future studies
are necessary to establish the tissue-specific action of global met-
formin administration to mice and cardiac-intrinsic mechanisms
determining beneficial effects of metformin treatment in ACHD.
5. CONCLUSIONS
The increased prevalence of ACHD in the population [1,2,66] and its
association with metabolic syndrome [67] call for mechanistic studies
to understand how cardiac energy flexibility correlates with heart
function in homeostasis and disease [39,68,69]. Surveillance of car-
diac performance combined with modulation of energy utilization could
lead to improvement of heart function and prevent heart failure in
ACHD, as demonstrated in this study using murine modeling. More
effective treatments for heart failure should move focus from solely
examining neurohormonal/unloading modulation to including correc-
tions for metabolically affected hearts [70]. The findings presented
here argue for manipulation of energy metabolism and mitochondrial
function as potential intervention targets to revert progression to heart
failure in ACHD.
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